Transferring our findings from bench to bedside could lead to a treatment strategy summarized as follows: (i) generation of a large amount of NKT cells (feasibility was shown in several studies [37,38,39], even though further modifications to improve NKT purity should be performed); (ii) electroporation with a CAR-mRNA encoding for a suitable antigen (e.g., CSPG4 for melanoma); (iii) cryopreservation (we could not find impairments on the viability of NKT cells through the latter); and (iv) reinfusion into the patient in repeated injections. The gene discussed is CSPG4; the disease is melanoma.